ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple antibody-drug conjugate (ADC) drug candidates targeting solid tumors and hematological malignancies that are in discovery, preclinical, and clinical development stages. The Company’s clinical stage programs are rinatabart sesutecan (Rina-S; PRO1184), an ADC targeting folate receptor alpha, PRO1160, an ADC targeting CD70, and PRO1107, an ADC targeting PTK7. ProfoundBio is headquartered in Seattle, WA, USA.

Xianfeng Qiyun

Gaorong Capital

K2VC

Chang'an Capital

Oriza Holdings

Sequoia Capital China

Lilly Asia Ventures

LYFE Capital

Surveyor Capital

T. Rowe Price

Ally Bridge Group

Piper Heartland Healthcare Capital

Janus Henderson Investors

LifeSci Venture Partners

Logos Capital

Medicxi

ProfoundBio

Are you going to be at #AACR2024 in San Diego? Don’t miss ProfoundBio’s presentations from our novel #ADC pipeline. Read more: https://lnkd.in/ga2ffDfq. #cancerresearch #biotech

Proud to share that ProfoundBio has secured $112 million in an oversubscribed Series B round, fueling our mission to advance novel cancer treatments, including advancing our flagship #ADC, rinatabart sesutecan (Rina-S) into late-stage clinical development. Deep gratitude to our esteemed life science investors for backing our vision. A big welcome to Andrew Lam, PharmD, Eric Dobmeier, and Enoch Kariuki, PharmD for joining our Board of Directors. With their guidance, we're diving deep into the next phase of innovation in #cancerresearch Learn more: https://lnkd.in/djG5g9EM 

#AntibodyDrugConjugates #Oncology #TargetedTherapy #SeriesBFinancing #BiotechInnovation

ProfoundBio is thrilled to announce the initiation of dosing in the Phase 1/2 clinical trial of PRO1107, marking a significant step forward in our efforts to develop antibody-drug conjugates (ADCs) with improved clinical outcomes for cancer patients. PRO1107 is a pioneering Protein Tyrosine Kinase 7 (PTK7)-targeted ADC that leverages our novel, proprietary hydrophilic MMAE-based linker-drug, aiming to set new standards in safety and efficacy for MMAE-based ADCs in the fight against cancer.

A heartfelt thank you to our dedicated investigators and the patients participating in this trailblazing research. Your involvement is pivotal in driving forward our mission to deliver groundbreaking treatments.

Read more: https://lnkd.in/gKXsEwsB

#ProfoundBio #ClinicalTrial #CancerResearch #InnovationInOncology #BiotechLinkedIn

📣 ProfoundBio is thrilled to announce that rinatabart sesutecan (Rina-S) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA)!

See our press release for more info 👉 : https://lnkd.in/gx9MUXiJ

ProfoundBio is a biotechnology company that specializes in the development of novel therapeutics aimed at treating various forms of cancer. The company leverages its proprietary technology platform to identify and advance new cancer therapies through the drug development pipeline.

COM:PROFOUNDBIO

ProfoundBio

Filings Not Available